Objective To study the effects and adverse reaction of imatinib mesylate used to prevent the recurrence of gastrointestinal stromal tumor (GIST) after resection. Methods 22 patients with primary gastrointestinal stromal tumor were included in the First Affiliated Hospital of Chongqing Medical University from January, 2007 to November, 2009 who received resection and were imageologically diagnosed as no residual tumor by enhanced CT or enhanced MRI after resection. They were all given imatinib mesylate 400 mg for oral use daily after resection (median-risk GIST: more than 1 year; high-risk GIST: more than 2 years). Patients’ 1-year and 2-year relapse-free survival (RFS) and adverse reaction were recorded during follow-up. Results Among 22 patients, there were 13 males and 9 females, with median age of 57.4 years, and 9 high-risk cases were included. The median follow-up lasted 34 months (24 to 48 months). Patients’ 1-year and 2-year RFS was 100% and 94.5%, respectively. Adverse reaction mainly included edema, nausea, abdominal pain, muscle or bone pain, thrombocytopenia, weakness, skin rashes, etc., most of which were mild or moderate and could be alleviated after treating symptoms. Conclusion Imatinib mesylate therapy given after resection is a safe and reliable method which could prolong RFS and prevent or delay the recurrence of GIST. However, further high-quality randomized controlled trial was required to verify its curative effects, since no control group has been set in our study.
目的 探讨甲磺酸伊马替尼治疗胃肠道间质瘤对患者细胞免疫功能的影响。方法 对病理诊断明确的16例行甲磺酸伊马替尼治疗的胃肠间质瘤患者的CD3+、CD4+、CD8+、CD4+/CD8+及NK细胞水平进行回顾性分析比较。结果 16例接受严格甲磺酸伊马替尼治疗的患者，其CD3+、CD4+、CD8+、CD4+/CD8+及NK细胞水平在甲磺酸伊马替尼治疗前、后无明显变化（Pgt;0.05）。结论 采用甲磺酸伊马替尼在对胃肠间质瘤患者进行分子靶向治疗时，对患者的细胞免疫功能无明显影响。
目的 探讨胃肠道外间质瘤（EGIST）的临床表现、外科治疗及预后。 方法 回顾性分析2004年1月－2010年6月收治的35例EGIST患者的临床资料。男26例，女9例；年龄33～78岁，平均56岁。病程5 d～8个月，平均2个月。临床表现主要有腹部不适、腹痛及腹部包块等。均在术前行CT或腹部增强CT等检查发现病灶，其中位于系膜16例，网膜15例，腹膜后4例。35例均行手术治疗。 结果 术后均由病理学检查及免疫组织化学检测确诊，肿瘤标本镜下均以梭形细胞为主；极低危险、低危险、中危险、高危险患者分别为0、3、0、32例。免疫组织化学检测示酪氨酸激酶受体（CD117）、DOG-1、骨髓干细胞抗原（CD34）、酸性钙结合蛋白、平滑肌肌动蛋白、结蛋白阳性率分别为91.4%（32/35）、100%（3/3）、71.4%（25/35）、8.6%（3/35）、22.9%（8/35）、0%（0/35）。15例患者均获随访，时间19～96个月，平均46个月。8例出现进展，7例病情稳定。 结论 EGIST发现时往往体积较大，预后较差，手术切除是首选治疗手段，甲磺酸伊马替尼对其具有较好的治疗效果。
Objective To investigate the effect of imatinib mesylate on radiation-induced lung injury mice and its influence on the oxidative stress and transforming growth factor-β1 (TGF-β1) expression in mice. Methods Forty-five C57BL/6 mice were divided into a treatment group, a control group and a model group. The treatment group and model group were given radiation of 18 Gy delivered in the thorax. After 4 h daily of the radiation, the treatment group received imatinib mesylate of 0.081 g/kg, while the other groups were given normal saline solution. The experiments were continued for 30 days. After the experiments, the lungs of mice were divided into 4 parts. The haematoxylin and eosin and immunohistochemical stain were prepared to observe the situation of pathology and TGF-β1. The lung homogenate was prepared and the levels of superoxide dismutase (SOD), malondialdehyde (MDA), total antioxidant capacity (T-Aoc) and glutathione peroxidase (GSH-PX) were detected. Results The levels of GSH-PX, T-Aoc and SOD were (173.15±12.21) U, (119.33±11.06) U/mgprot and (1.73±0.33) nmol/mgprot in the treatment group, significantly higher than the control group, while the levels of MDA was (0.68±0.08) nmol/mgprot, significantly lower than the control group (P<0.05). The HE and immunohistochemical stain showed that there were mild alveolar inflammatory changes in the treatment group while such changes were serious in the model group. The scores of HE and immunohistochemical were 1.26±0.12 and 0.31±0.12 in the treatment group, significantly lower than those in the control group (P<0.05). Conclusion The imatinib mesylate can effectively ameliorate the oxidative stress and inhibite TGF-β1 expression in radiation-induced lung injury mice.